 |
Stroke Weekly News: 726 headlines |
|
|||||||||||||
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!| Executive Editor..Anne Merete Robbs CEO..............Stan Swartz |
||||
 |
||||
|
||||
| 4 TALES OF NEUROSURGERY & A PIANO CONCERT BY DR. SPETZLER... Plus 2 books written by Survivors for Survivors! |
||||
 |
||||
| Robert F. Spetzler M.D. Director, Barrow Neurological Institute J.N. Harber Chairman of Neurological Surgery Professor Section of Neurosurgery University of Arizona |
||||
| TALES OF NEUROSURGERY: | ||||
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade! |
||||
| Lou Grubb Anurism |
||||
| The young Heros - kids who are confronted with significant medical problems! |
||||
| 2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others! |
||||
| A 1 MINUTE PIANO CONCERT BY DR. SPETZLER |
||||
| Sources used by our Heart & Stroke News Research Team: | ||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||
| Links | ||||
|
||||
| Archives | ||||
| January 2005 | ||||
| February 2005 | ||||
| March 2005 | ||||
| April 2005 | ||||
| May 2005 | ||||
| June 2005 | ||||
| July 2005 | ||||
| August 2005 | ||||
| September 2005 | ||||
| October 2005 | ||||
| November 2005 | ||||
| December 2005 | ||||
| January 2006 | ||||
| February 2006 | ||||
| March 2006 | ||||
| April 2006 | ||||
| May 2006 | ||||
| June 2006 | ||||
| July 2006 | ||||
| August 2006 | ||||
| September 2006 | ||||
| October 2006 | ||||
| November 2006 | ||||
| December 2006 | ||||
| January 2007 | ||||
| February 2007 | ||||
| March 2007 | ||||
| June 2007 | ||||
| April 2008 | ||||
| May 2008 | ||||
| January 2009 | ||||
| January 2014 |
Friday
The New York Times > Health > Vital Signs: Treatments: Artery Cleanup Misses Its Mark
The New York Times > Johnson & Johnson Adds Data on Deaths to Label on Heart Treatment
Tuesday
Childhood obesity: early prevention offers best solution
Fatness, despite fitness, is linked with cardiovascular risk factors
Enlarged waist elevated triglycerides = heart, stroke risks for women
Combo Therapy Lowers Blood Clot Risk After Stroke
Combo Therapy Lowers Blood Clot Risk After Stroke
Bypass Surgery Doesn't Harm Cognitive Ability
Monday
VIDEOS OF SURGICAL PROCEDURES...each is one hour
MedlinePlus: Stroke treatment advances reported
MedlinePlus: 80-year-olds Do Well with Heart Artery Bypass
Saturday
NIH/NHLBI News Release--NHLBI Study: The Promise of New Medical Uses for Sodium Nitrite for Heart Attack and Organ Damage
NIH/NHLBI News Release--New Study Shows Antibiotic Treatment Does Not Reduce Risk of Secondary Cardiac Events, April 20, 2005
"LOU GRUBB GIVES ADVICE TO FELLOW SURVIVORS OF ANEURISMS".....A WC HEALTH CHANNEL FILM
The New York Times > Women Struggle for Parity of the Heart
Friday
Ivanhoe's Medical Breakthroughs - Statins Help Stroke Recovery
LINK: "A new study shows taking cholesterol-lowering drugs called statins helps stroke patients recover. "
Tuesday
JAMA -- Excess Deaths Associated With Underweight, Overweight, and Obesity, April 20, 2005, Flegal et al. 293 (15): 1861
Well Documented Risk Factors for Recurrent Stroke Well Documented Risk Factors for Recurrent Stroke
What Proportion of Stroke Is Not Explained by Classic Risk
Monday
ABC News: Can 'Good' Cholesterol Zap Heart Disease?
Thursday
MedlinePlus: Red wine is indeed good for the heart
Sunday
The New York Times: The High Cost of Clutching Your Chest
Thursday
FDA QUESTIONS AND ANSWERS
FDA Public Health Advisory
FDA PRESS RELEASE: FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
FDA: COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
CLICK HERE TO BE LINKED TO THE COMPLETE FDA ARTICLE"The Food and Drug Administration (FDA) has asked Pfizer to voluntarily remove Bextra (valdecoxib) from the market. FDA is also asking manufacturers of all marketed prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Celebrex (celecoxib), a COX-2 selective NSAID, to revise the labeling (package insert) for their products to include a boxed warning, highlighting the potential for increased risk of cardiovascular (CV) events and the well described, serious, potential life-threatening gastrointestinal (GI) bleeding associated with their use.
Manufacturers of non-prescription (over-the-counter) NSAIDs are also being asked to revise their labeling to provide more specific information about the potential CV and GI risks of their individual products and remind patients that these products of the limited dose and duration of treatment in accordance with the package instructions.
In making these decisions, the Center for Drug Evaluation and Research (CDER) considered the risk/benefit profile for each of the drugs. Also considered was;
review of the regulatory histories and new drug application (NDA) databases of the various NSAIDs,
FDA and sponsor background documents prepared for the joint Advisory Committee meeting of FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees, held February 16-18, 2005,"
all materials and data submitted by other stakeholders to the Advisory Committee meeting,
presentations made at the joint meeting the specific votes and recommendations made by the joint Committee.
Further information regarding the decisions being announced and specific details regarding the individual products can be found within the documents posted to this Web page.
Manufacturers of non-prescription (over-the-counter) NSAIDs are also being asked to revise their labeling to provide more specific information about the potential CV and GI risks of their individual products and remind patients that these products of the limited dose and duration of treatment in accordance with the package instructions.
In making these decisions, the Center for Drug Evaluation and Research (CDER) considered the risk/benefit profile for each of the drugs. Also considered was;
review of the regulatory histories and new drug application (NDA) databases of the various NSAIDs,
FDA and sponsor background documents prepared for the joint Advisory Committee meeting of FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees, held February 16-18, 2005,"
all materials and data submitted by other stakeholders to the Advisory Committee meeting,
presentations made at the joint meeting the specific votes and recommendations made by the joint Committee.
Further information regarding the decisions being announced and specific details regarding the individual products can be found within the documents posted to this Web page.
BREAKING NEWS!!!! new warning labeling for CELEBREX & over-the-counter NSAIDs
LINK FOR FULL ARTICLE"April 7, 2005 — At the request of the U.S. Food and Drug Administration (FDA), Pfizer, Inc, has agreed to suspend sales and marketing of valdecoxib (Bextra) pending further discussions with the agency. The FDA claims that the drug's overall risks outweigh the potential benefits, according to an alert sent today from MedWatch, the FDA's safety information and adverse event reporting program.
The decision follows a joint public meeting of the FDA’s Arthritis Drugs/Drug Safety and Risk Management Advisory committees, held in February to review safety data compiled from clinical trials and postmarketing reports."
As a result of the meeting, the FDA has also asked manufacturers to revise the labeling for all prescription NSAIDs, including celecoxib (Celebrex, made by Pfizer, Inc), to include stronger warnings on the increased risk of CV events and potentially life-threatening gastrointestinal (GI) bleeding associated with their use.
Labels for over-the-counter NSAIDs will also include more specific information concerning CV and GI risks, and they will warn of potential skin reactions. The labeling revisions do not apply to aspirin because it has been shown in clinical trials to reduce the risk of serious adverse CV events in certain populations."
The decision follows a joint public meeting of the FDA’s Arthritis Drugs/Drug Safety and Risk Management Advisory committees, held in February to review safety data compiled from clinical trials and postmarketing reports."
As a result of the meeting, the FDA has also asked manufacturers to revise the labeling for all prescription NSAIDs, including celecoxib (Celebrex, made by Pfizer, Inc), to include stronger warnings on the increased risk of CV events and potentially life-threatening gastrointestinal (GI) bleeding associated with their use.
Labels for over-the-counter NSAIDs will also include more specific information concerning CV and GI risks, and they will warn of potential skin reactions. The labeling revisions do not apply to aspirin because it has been shown in clinical trials to reduce the risk of serious adverse CV events in certain populations."
[EDUCATION] Brigham and Women's Hospital: Stroke Symptoms and Recovery, Causes of Strokes
Wednesday
The New England Journal of Medicine -- Statins and Over-the-Counter Availability
Tuesday
Enhanced Antithrombotic Effect of Warfarin Associated With Low-Dose Alcohol Consumption
VCU Research Shows Viagra Prevents Anti-cancer Drug Induced Heart Damage
Sunday
Aspirin Beats Coumadin for Brain Blockage
LINKThat's both good news and bad news. The good news is that many patients with blocked brain arteries may be able to avoid the expense and complications of treatment with Coumadin (also known by its generic name, warfarin). The bad news is that despite treatment, more than one in five patients suffers stroke, brain hemorrhage, or death within two years.
Brain artery narrowing -- what doctors call intracranial arterial stenosis -- happens when fatty deposits build up in the blood vessels of the brain, reducing blood flow. It causes about one in 10 strokes and transient ischemic attacks (TIAs), also known as ministrokes.
Brain artery narrowing -- what doctors call intracranial arterial stenosis -- happens when fatty deposits build up in the blood vessels of the brain, reducing blood flow. It causes about one in 10 strokes and transient ischemic attacks (TIAs), also known as ministrokes.
Harvard/Massachusets General Hospital: Optical technique identifies vulnerable plaques in cardiac patients
Saturday
The NEW ENGLAND JOURNAL of MEDICINE - The Puzzle of Aspirin and Sex
Friday
BBC NEWS 'Heavier drinkers risk strokes'
LINK: "Men who drink heavily are at increased risk of stroke, research shows. But lighter drinkers, particularly those who have a glass of red wine each day, reduce their risk of stroke, heart disease and diabetes. "
Women & Cardiovascular Disease
The facts surrounding women and heart disease can be frightening to think about.
LINKThe good news is that many of the risk factors associated with cardiovascular disease (CVD) can be changed and avoided to prevent premature death or unwanted complications.